Sepracor, Inc. (NASDAQ: SEPR), a research-based pharmaceutical company, has focused their efforts on treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products designed to serve large and growing markets. The company’s drug development program has proven its success by yielding a portfolio of pharmaceutical products and candidates. The focus of the program is on treating respiratory and central nervous system (CNS) disorders. For further information, visit the Company’s web site at www.sepracor.com.
- 18 years ago
QualityStocks
Sepracor, Inc. (NASDAQ: SEPR)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Streamex Corp. (NASDAQ: STEX) Announces $1 Million Institutional Allocation to GLDY-Based Investment Strategy
Streamex (NASDAQ: STEX) announced that an institutional investment manager has launched an investment strategy using…
-
QualityStocksNewsBreaks – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) Subsidiary MindWave Signs 12-Month Technology Services Agreement with AQUAE Holdings
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) subsidiary MindWave Innovations Inc. signed a 12-month technology…
-
QualityStocksNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) President Discusses Critical Minerals Strategy, Project Development on MiningNewsWire Podcast
Greenland Mines (NASDAQ: GRML) President Dr. Bo Møller Stensgaard joined the latest episode of The…